Lead Product(s) : Etripamil
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Issues Complete Response Letter for Etripamil for PSVT
Details : Cardamyst (etripamil), a novel calcium channel blocker nasal spray, is being investigated for the management of paroxysmal supraventricular tachycardia.
Product Name : Cardamyst
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 28, 2025
Lead Product(s) : Etripamil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etripamil
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST„
Details : Cardamyst (etripamil), a novel calcium channel blocker nasal spray, is being investigated for the management of paroxysmal supraventricular tachycardia.
Product Name : Cardamyst
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 29, 2024
Lead Product(s) : Etripamil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etripamil
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Milestone Resubmits NDA for Etripamil for Paroxysmal Supraventricular Tachycardia
Details : MSP-2017 (etripamil) is a fast-acting, intranasally administered calcium-channel blocker, which is being evaluated for the treatment of Paroxysmal Supraventricular Tachycardia.
Product Name : Cardamyst
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 28, 2024
Lead Product(s) : Etripamil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etripamil
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Piper Sandler
Deal Size : $30.0 million
Deal Type : Public Offering
Milestone Pharmaceuticals Prices $30 Million Public Offering of Common Shares and Warrants
Details : Milestone intends to use the net proceeds from the Offering to continue the development of Cardamyst (etripamil) in its lead indication of paroxysmal supraventricular tachycardia.
Product Name : Cardamyst
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 29, 2024
Lead Product(s) : Etripamil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Piper Sandler
Deal Size : $30.0 million
Deal Type : Public Offering
Lead Product(s) : Etripamil
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Piper Sandler
Deal Size : Undisclosed
Deal Type : Public Offering
Milestone Proposes Public Offering of Common Shares and Pre-Funded Warrants
Details : Milestone intends to use the net proceeds from the offering to continue the development of MSP-2017 (etripamil) in its lead indication of paroxysmal supraventricular tachycardia.
Product Name : Cardamyst
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 28, 2024
Lead Product(s) : Etripamil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Piper Sandler
Deal Size : Undisclosed
Deal Type : Public Offering
Lead Product(s) : Etripamil
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil to Treat PSVT
Details : MSP-2017 (etripamil) is a fast-acting, intranasally administered calcium-channel blocker, which is being evaluated for the treatment of Paroxysmal Supraventricular Tachycardia.
Product Name : Cardamyst
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 26, 2024
Lead Product(s) : Etripamil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etripamil
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MSP-2017 (etripamil) is a novel calcium channel blocker. It is under phase 3 clinical development for the treatment of paroxysmal supraventricular tachycardia.
Product Name : Cardamyst
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 26, 2023
Lead Product(s) : Etripamil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etripamil
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil
Details : MSP-2017 (etripamil) is Milestone's lead investigational product. It is a novel calcium channel blocker nasal spray being developed for elevated and often highly symptomatic heart-rate attacks associated with PSVT and atrial fibrillation with a rapid ven...
Product Name : Cardamyst
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 24, 2023
Lead Product(s) : Etripamil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etripamil
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MSP-2017 (etripamil) is a calcium channel antagonist potentially for the treatment of paroxysmal supraventricular tachycardia. It is designed to be a rapid-response therapy for elevated and often highly symptomatic heart rate attacks associated with PSVT...
Product Name : Cardamyst
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 03, 2023
Lead Product(s) : Etripamil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etripamil
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : RTW Investments
Deal Size : $125.0 million
Deal Type : Financing
Details : The net proceeds from the financing will be used to support the advancement of MSP-2017 (etripamil), a novel calcium channel blocker nasal spray, for paroxysmal supraventricular tachycardia.
Product Name : Cardamyst
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 28, 2023
Lead Product(s) : Etripamil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : RTW Investments
Deal Size : $125.0 million
Deal Type : Financing